Tarsus Pharmaceuticals

TARSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.624 B

$77.46 -0.81%

Close of 21 Sept 2026

Revenue

$451.4M

#1959 by revenue

Earnings

-$66.0M

Loss-making

Shares outstanding

43,882,996

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#24Adaptive BiotechnologiesADPT$4.45B
#25Relay TherapeuticsRLAY$3.99B
#26Tarsus PharmaceuticalsTARS$3.62B
#27Denali TherapeuticsDNLI$3.27B
#28Beam TherapeuticsBEAM$2.61B

What if Tarsus Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$646,996.41

Per share 8,353× higher

Bitcoin $1.72T

$36,754.47

Per share 474× higher

Nvidia $5.48T

$117,111.78

Per share 1,512× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Tarsus Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.